Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00 at Truist Financial

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price boosted by Truist Financial from $38.00 to $42.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently commented on the stock. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Scotiabank raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.56.

Teva Pharmaceutical Industries Stock Down 0.8%

Shares of NYSE TEVA opened at $34.15 on Wednesday. The stock has a market capitalization of $39.26 billion, a P/E ratio of 28.46, a PEG ratio of 1.96 and a beta of 0.70. The stock’s fifty day moving average is $32.40 and its 200 day moving average is $24.87. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 422,060 shares of company stock valued at $12,254,965. Company insiders own 0.49% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth about $25,000. Allworth Financial LP raised its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. Grove Bank & Trust lifted its stake in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $41,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target and reiterated a Buy, lifting the PT to $45 (from $36), signaling expectations for double-digit EPS growth through 2026 — a clear bullish catalyst for TEVA. Goldman Sachs upgrade
• Positive Sentiment: Truist raised its price target to $42 and maintains a Buy rating, implying meaningful upside from current levels and reinforcing analyst conviction. Truist PT raise
• Positive Sentiment: Teva and partner Sanofi reported positive Phase 2b maintenance data for duvakitug in ulcerative colitis and Crohn’s disease showing clinically meaningful, durable efficacy — this advances TEVA’s biologics pipeline and potential future revenue streams. Duvakitug phase 2b data
• Positive Sentiment: Additional coverage highlights positive longer-term RELIEVE UCCD extension results for duvakitug showing lasting relief in inflammatory bowel disease patients — supportive for commercial potential and partner economics. RELIEVE UCCD extension results
• Positive Sentiment: Teva hosted an investor call and published a transcript/slideshow discussing the duvakitug Phase 2b maintenance top-line results, giving investors direct management commentary on next steps and timelines. Investor call / transcript
• Neutral Sentiment: Market roundup: a Benzinga compilation shows 13 analysts weighing in on TEVA (ratings/targets updated), reflecting growing analyst attention but mixed timing on upgrades. Analyst roundup
• Neutral Sentiment: Brokerage consensus profiles TEVA as a “Moderate Buy,” suggesting broad but not unanimous bullishness among sell-side firms. Brokerage consensus

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.